November 5, 2024 12:14 PM ESTUpdated November 6, 07:47 AM
R&D

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

Katherine Lewin

News Reporter

John­son & John­son’s CD38 in­hibitor Darza­lex showed a ben­e­fit in de­lay­ing or pre­vent­ing dis­ease pro­gres­sion in pa­tients with high-risk smol­der­ing mul­ti­ple myelo­ma, a pre­cur­sor to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times